

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
*(Not for submission under 37 CFR 1.99)*

Application Number	10820618
Filing Date	2004-04-07
First Named Inventor	HUANG, YADONG
Art Unit	1646
Examiner Name	Pak, Michael D.
Attorney Docket Number	GLAD-217CON

U.S. PATENTS							<a href="#">Remove</a>
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button. [Add](#)

U.S. PATENT APPLICATION PUBLICATIONS							<a href="#">Remove</a>
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

FOREIGN PATENT DOCUMENTS							<a href="#">Remove</a>	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button							<a href="#">Add</a>
NON-PATENT LITERATURE DOCUMENTS							<a href="#">Remove</a>
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					Ts

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10820618
Filing Date	2004-04-07
First Named Inventor	HUANG, YADONG
Art Unit	1646
Examiner Name	Pak, Michael D.
Attorney Docket Number	GLAD-217CON

1	LYNCH, et al. A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury. <i>Exp Neurol.</i> 2005 Mar;192(1):109-16.	<input type="checkbox"/>
2	MCADOO, et al. Intrathecal administration of a novel apoE-derived therapeutic peptide improves outcome following perinatal hypoxic-ischemic injury. <i>Neurosci Lett.</i> 2005 Jun 24;381(3):305-8.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button [Add](#)

**EXAMINER SIGNATURE**

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.